Gan & Lee Pharmaceuticals subsidiary obtains registration approval for sitagliptin metformin tablets (II) drug.

Gan & Lee Pharmaceuticals (603087.SH) announced that its wholly-owned subsidiary Gan & Lee Pharmaceuticals Shandong Co., Ltd. recently received the registration certificate for the product of SGLT-2 inhibitor and metformin hydrochloride tablets (Type II) issued by the National Medical Products Administration with acceptance number CYHS2403373 and drug registration certificate number 2026S00914. SGLT-2 inhibitor and metformin hydrochloride tablets (Type II) is a fixed-dose combination formulation composed of empagliflozin and metformin hydrochloride. It can be used in conjunction with diet and exercise therapy for type 2 diabetes patients who have inadequate blood sugar control with metformin monotherapy or are currently undergoing combination therapy with both drugs.